Clarus Wealth Advisors Purchases Shares of 1,766 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Clarus Wealth Advisors acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,766 shares of the company’s stock, valued at approximately $253,000.

A number of other large investors have also made changes to their positions in the stock. Park Avenue Securities LLC lifted its position in shares of Neurocrine Biosciences by 23.3% in the 4th quarter. Park Avenue Securities LLC now owns 7,080 shares of the company’s stock worth $966,000 after acquiring an additional 1,336 shares during the period. Tealwood Asset Management Inc. lifted its position in Neurocrine Biosciences by 1.0% in the fourth quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock worth $1,626,000 after purchasing an additional 118 shares during the period. Pallas Capital Advisors LLC boosted its stake in Neurocrine Biosciences by 19.0% during the fourth quarter. Pallas Capital Advisors LLC now owns 7,673 shares of the company’s stock worth $1,047,000 after buying an additional 1,225 shares in the last quarter. First Hawaiian Bank increased its holdings in Neurocrine Biosciences by 21.3% in the 4th quarter. First Hawaiian Bank now owns 12,243 shares of the company’s stock valued at $1,671,000 after buying an additional 2,150 shares during the period. Finally, Everence Capital Management Inc. acquired a new position in shares of Neurocrine Biosciences in the 4th quarter valued at $476,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity

In other news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the transaction, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. The trade was a 30.32 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,694 shares of company stock valued at $479,230. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $139.51 on Wednesday. The stock has a market capitalization of $14.12 billion, a PE ratio of 37.40 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The stock has a 50 day moving average price of $130.79 and a 200 day moving average price of $131.03.

Analysts Set New Price Targets

Several research firms recently issued reports on NBIX. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. BMO Capital Markets dropped their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. UBS Group upped their price target on Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Piper Sandler reissued an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Finally, Wedbush restated an “outperform” rating and issued a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $164.81.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.